Compare

Revelation Biosciences, Inc. vs Curanex Pharmaceuticals Inc vs NewcelX Ltd. vs PRF Technologies Ltd.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Revelation Biosciences, Inc. REVB	Curanex Pharmaceuticals Inc CURX	NewcelX Ltd. NCEL	PRF Technologies Ltd. PRFX
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	n/a	$17.0K
Revenue growth (YoY)	n/a	n/a	n/a	n/a
Gross margin	n/a	n/a	n/a	-311.8% (computed)
Operating margin	n/a	n/a	n/a	n/m
Net margin	n/a	n/a	n/a	n/m
Net income	-$8.91M	-$4.23M	-$8.30M	-$5.02M
EPS (Diluted)	-$23.95	-$0.17	$2.16	-$7.47
Operating cash flow	-$8.27M	-$10.48M	-$2.77M	-$3.96M
Free cash flow	n/a	n/a	-$2.77M	-$3.96M
Cash & equivalents	$10.70M	$5.00M	$2.20M	$3.12M
Total assets	$11.58M	$11.58M	$11.45M	$12.00M
Total liabilities	$2.72M	$361.0K	$4.20M	$2.71M
Shareholders' equity	$8.86M	$11.22M	$7.25M	$8.54M
Return on year-end equity	-100.6%	-37.7%	-114.5%	-58.8%
Shares outstanding	1.58M	28.34M	4.80M	830.6K

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Revelation Biosciences, Inc.	Curanex Pharmaceuticals Inc	NewcelX Ltd.	PRF Technologies Ltd.
Latest	n/a	n/a	n/a	$17.0K Ended 2025-12-31
1 year earlier	n/a	n/a	n/a	$0 Ended 2024-12-31
2 years earlier	n/a	n/a	n/a	$0 Ended 2023-12-31
3 years earlier	n/a	n/a	n/a	n/a
4 years earlier	n/a	n/a	n/a	n/a